Browse
You are looking at 61 - 63 of 63 items for
Department of Medicine, Mater Dei Hospital, Msida, Malta
Search for other papers by Sarah Craus in
Google Scholar
PubMed
Department of Medicine, Mater Dei Hospital, Msida, Malta
Search for other papers by Mark Gruppetta in
Google Scholar
PubMed
Background
Despite being benign tumours, craniopharyngiomas are challenging to manage and can cause significant morbidity and mortality in both the paediatric and adult population. The aim of the study was to analyse the epidemiology of craniopharyngiomas, patient and tumour characteristics through a population-based study in Malta, enabling a better quantification of the disease burden.
Methods
Thorough research was carried out to identify the number of patients who were diagnosed with craniopharyngiomas. Epidemiological data, including both standardised incidence rates (SIR) and prevalence rates, were established in a well-defined population. For incidence estimates, patients who were diagnosed between 2008 and 2019 were included. The background population formed 4.8 million patient-years at risk.
Result
Twenty-nine subjects were identified and included in our study. The overall SIR was 0.3/100,000/year, with a higher SIR for males compared to females (0.4/100,000/year and 0.2/100,000/year, respectively). The highest SIR was recorded in the 10–19 year age group. The estimated prevalence rate amounted to 5.27/100,000 people, with a lower prevalence rate for childhood-onset when compared to the adult-onset category (2.03/100,000 vs 3.24/100,000 people). The median longest tumour diameter was 31.0 mm (IQR 21–41), with a statistically significant difference between childhood- and adult-onset disease; 43.0 mm (IQR 42.5–47.25) vs 27.0 mm (IQR 20.55–31.55) (P = 0.011).
Conclusion
Through this population-based study, accurate and up-to-date prevalence and incidence rates for craniopharyngiomas are reported. These provide a clearer reflection of the true health burden of the disease.
Search for other papers by Patrick W Owens in
Google Scholar
PubMed
Search for other papers by Terri Patricia McVeigh in
Google Scholar
PubMed
Search for other papers by Nicola Miller in
Google Scholar
PubMed
Search for other papers by Carole Guerin in
Google Scholar
PubMed
Search for other papers by Frederic Sebag in
Google Scholar
PubMed
Search for other papers by Denis Quill in
Google Scholar
PubMed
Search for other papers by Marcia Bell in
Google Scholar
PubMed
Search for other papers by Michael J Kerin in
Google Scholar
PubMed
Search for other papers by Aoife J Lowery in
Google Scholar
PubMed
Objective
FOXE1 is an intronless gene on chromosome 9 which plays a significant role in thyroid morphogenesis. Mutations in FOXE1 are associated with thyroid phenotypes including congenital hypothyroidism, thyroid dysgenesis and thyroid cancer. This study aims to investigate the frequency and impact of a SNP (rs965513, G>A) at 9q22.23 in a Western European cohort of patients with differentiated thyroid cancer(DTC), compared to controls.
Design
This is a candidate gene case control study.
Methods
277 patients with histologically confirmed DTC were recruited from tertiary referral centres in Ireland and France. 309 cancer-free controls were recruited from the community. DNA was extracted from buccal swabs or whole blood of control subjects and patients with DTC. Allelic and genotypic frequencies among patients were compared with controls, to assess the risk for disease conferred by homozygous and heterozygous carriers compared to WT genotypes. Genotyping was performed using Taqman-based PCR.
Results
277 patients with confirmed DTC and 309 non-cancer controls were genotyped for the variant (rs965513). The frequency of the minor allele among cases was 0.45 compared to 0.34 among controls. The genotypic odds ratio for heterozygotes was 1.66 (CI 1.16–2.39, P =0.00555), increasing to 2.93 (CI 1.70–5.05, P =0.00007) for rare homozygotes. All subjects were in Hardy-Weinberg equilibrium (±χ 2, P =0.09, P =0.07 respectively).
Conclusions
This FOXE1 polymorphism is a low penetrance variant associated with DTC susceptibility in this cohort. The minor allele was identified among patients with thyroid cancer significantly more frequently than controls. An allele dosage effect was observed, with rare homozygous genotypes conferring greater risk than heterozygotes.
Search for other papers by Edward P Gelmann in
Google Scholar
PubMed
